[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sternotomy-closureopen-heart-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sternotomy-closureopen-heart-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100621098","adjustable-carbon-fiber-sternal-plates-for-sternotomy-closure-100621098",false,"NCT07366203","Adjustable Carbon Fiber Sternal Plates for Sternotomy Closure","Clinical Investigation to Evaluate the Use of Adjustable Carbon Fiber Sternal Plates for Sternotomy Closure","FIX IT ALL","Inclusion Criteria:\n\n* Patient ≥ 18 years old.\n* Patient who must undergo surgery in which a median or an upper partial sternotomy is indicated.\n* Patients capable of giving their voluntary informed consent to participate in the clinical investigation and from whom written consent has been obtained.\n* Patient able and willing to meet the protocol requirements and to follow postoperative care instructions\n\nExclusion Criteria:\n\n* Patient with sternal anomalies, such as bone tumours located in the sternum.\n* Patient with limited sternum bone blood supply.\n* Patient with suspected or known allergies or intolerances to the implants materials: PEEK, carbon fibre, titanium, stainless steel.\n* Patient with severe osteoporosis or other degenerative bone diseases that affect the sternum.\n* Pregnant or breastfeeding patient or patient planning to become pregnant during the first 6 months after surgery.\n* Patient who is currently using opioid analgesics (e.g., morphine, oxycodone, hydrocodone, fentanyl, tramadol) for the management of chronic or acute pain.\n* Patient with diagnosis of dementia with a mental status score (MMSE) \\\u003C 20.\n* Patient with life expectancy lower than 6 months.\n* Patient with any other medical process that may compromise or limit the adequate functionality of the implants.\n* Patient involved in other interventionist clinical trial or that have been involved in other interventionist clinical trial during the previous 4 weeks.\n* Patient with signs of latent or active infection or inflammation on the surgical site.\n* Patient with insufficient quantity or quality of sternum bone, or other severe structural bone damage.\n* Patient for whom the closure technique cannot ensure sufficient sternal fixation.\n* Parasternal sternotomy.\n* Patient with intraoperative conditions that may compromise or limit the adequate functionality of the implants or that may prevent the surgeon to use the sternal closure system or that cannot be closed following the product instructions for use","ALL","18 Years",{"count":20,"type":21},190,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if a new medical device (SC03 plates) to close the sternum after a sternotomy in patients that have been operated of a cardiac surgery, is safe and effective. The main question it aims to answer is:\n\nDo patients that have the sternum closed with the SC03 plates present a stable sternum one month after surgery?\n\nResearchers will compare the SC03 plates with stainless steel wires (current standard of care to close the sternum).\n\nParticipants will:\n\n* be implanted with the SC03 or stainless steel wires.\n* visit the clinic one month and six months after surgery\n* Keep a diary of their symptoms and analgesia use",[27],"Sternotomy Closure,Open Heart Surgery","NOT_YET_RECRUITING","2026-01-16",{"date":31,"type":32},"2026-01-26","ACTUAL",{"date":34,"type":21},"2026-02",{"date":36,"type":21},"2027-12",{"name":38,"class":39},"NEOS Surgery","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100593961","phase-3-botulinum-toxin-injection-after-sternotomies-to-improve-scar-aspect-and-impact-100593961","NCT07013240","Botulinum Toxin Injection After Sternotomies to Improve Scar Aspect and Impact","Immediate Post-surgical Botulinum Toxin Injections to Prevent Dystrophic Scars After Sternotomy : a Placebo-controlled Randomized Clinical Trial","BotuCiSter","Inclusion Criteria:\n\n* Patient aged 18 years or older\n* Scheduled sternotomy at Bordeaux University Hospital within the next 4 months\n* Person affiliated with or benefiting from a social security system\n* Patient able to attend follow-up visits required by the study\n* Free, informed, and written consent signed by the participant or an impartial witness (in case the participant is unable to write) and the investigator (no later than the day of inclusion)\n\nExclusion Criteria:\n\n* Known allergy to botulinum toxin type A or any excipient in BOTOX® (human albumin, sodium chloride)\n* Neuromuscular transmission disorder (myasthenia gravis or Lambert-Eaton syndrome)\n* Motor peripheral neuropathy (such as amyotrophic lateral sclerosis or motor neuropathy)\n* Infection at the injection sites\n* Pregnancy or breastfeeding\n* Person under protection measures",{"count":49,"type":21},50,[51],"PHASE3","Sternotomy scars, which are localized in a high-tension area are often dystrophic, hypertrophic or keloidal, and can be difficult to accept to patients who already endured a heavy intervention with high psychologic impact. The investigators wish to evaluate immediate post-surgical injection of botulinum toxin to improve scar aspect and impact. A randomized, placebo-controlled, split-scar clinical trial will determine the improvement of scar aspects assessed by standardized scores (SBSES, POSAS), patient satisfaction and tolerance.",[27],[55,56,57,58],"scar","keloid","botulinum toxin","sternotomy","2025-06-02",{"date":61,"type":32},"2025-06-10",{"date":63,"type":21},"2025-07-05",{"date":65,"type":21},"2027-02-28",{"name":67,"class":68},"University Hospital, Bordeaux","OTHER",1]